ORKA-002 compared with placebo for adults with hidradenitis suppurativa
Tests ORKA-002 against placebo in adults with moderate-to-severe hidradenitis suppurativa.
Key facts
- Who runs it
- Oruka Therapeutics, Inc.
- Where
- Baton Rouge, Birmingham, Canton, Chapel Hill, Chicago, Cromwell, Dallas, Fountain Valley, Los Angeles, Missouri City, New Brighton, New Orleans, New York, Omaha, Plainfield, Portland, San Antonio, Sandy Springs, Smyrna, and St Louis, United StatesSee the 20 sitesAlso in 1 other country, 5 sites
- Trial code
- Registry title
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 200 people, planned
- Started
- 21 Aug 2026
- Expected to end
- Sept 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- ORKA-002
- Placebo
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate-to-severe hidradenitis suppurativa (HS), a long-term skin disease with painful lumps. It compares ORKA-002 with a placebo (dummy treatment).
- Age
- 18 Years to 79 Years
- Sex
- All sexes can join.
- Disease stage
- Moderate-to-severe HS. Signs and symptoms for at least 6 months. Lesions in 2 or more separate body areas, at least one at Hurley Stage II or III.
- Earlier treatment
- Antibiotics taken by mouth or injection (systemic) for HS did not work well enough, HS came back after stopping them, they were not tolerated, or the person cannot take them.
Main reasons for not taking part
- Another active skin disease or condition that could make it hard to assess HS
- A diagnosed or suspected autoimmune disease
- Another inflammatory condition besides HS
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Has signs and symptoms of HS for at least 6 months
- Has HS lesions present in ≥ 2 distinct anatomic areas, one of which must be at least Hurley Stage II or III
- Has a history of inadequate response to systemic antibiotic treatment for HS, exhibited recurrence of HS symptoms after discontinuation of systemic antibiotics for HS, demonstrated intolerance to systemic antibiotics for HS, or has a contraindication to systemic antibiotics for HS
Who cannot take part
- Presence of any other active skin disease or condition that may interfere with the assessment of HS
- Diagnosis or suspected diagnosis of autoimmune diseases or inflammatory conditions other than HS
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Where in United States
Also in 1 other country, 5 sites
- Baton Rouge, LouisianaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Birmingham, AlabamaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Canton, MichiganHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Chapel Hill, North CarolinaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Chicago, IllinoisHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Cromwell, ConnecticutHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Dallas, TexasHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Fountain Valley, CaliforniaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Los Angeles, CaliforniaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Missouri City, TexasHospital not named in the registryContact: Oruka Investigative SiteTaking people
- New Brighton, MinnesotaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- New Orleans, LouisianaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- New YorkHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Omaha, NebraskaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Plainfield, IndianaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Portland, OregonHospital not named in the registryContact: Oruka Investigative SiteTaking people
- San Antonio, TexasHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Sandy Springs, GeorgiaHospital not named in the registryContact: Oruka Investigative SiteTaking people
- Smyrna, TennesseeHospital not named in the registryContact: Oruka Investigative SiteTaking people
- St Louis, MissouriHospital not named in the registryContact: Oruka Investigative SiteTaking people
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
The 2 groups in the trial
- Induction Period - Arm 1 (ORKA-002)Treatment being tested
Participants will receive ORKA-002 per protocol Induction regimen.
Treatment: ORKA-002
- Induction Period - Arm 2 (Placebo)Treatment being tested
Participants will receive Placebo per protocol Induction regimen.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa
- Plain-language title
- ORKA-002 compared with placebo for adults with hidradenitis suppurativaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07783542, who can take part
- Record updated
- 29 October 2026